Longevity Drug Index / Captopril
Captopril
A classic blood pressure drug that produced a small lifespan gain in the NIA mouse program.
How it works
Captopril blocks angiotensin-converting enzyme, which makes the hormone angiotensin II. With less angiotensin II, blood vessels relax, blood pressure falls and the body holds on to less salt and water. It also raises levels of bradykinin, a molecule that widens blood vessels.
How it could help longevity
Beyond raising blood pressure, angiotensin II promotes inflammation, oxidative stress and scarring in the heart, kidneys and blood vessels. Mice bred without the main angiotensin II receptor live longer, which suggests that damping this system could slow some aspects of aging.
Animal studies
- NIA Interventions Testing Program, 2022Captopril given from early adulthood produced small but significant increases in lifespan in both male and female mice.
- Angiotensin receptor knockout mice, 2009Mice lacking the AT1 receptor for angiotensin II lived longer and had less organ damage with age.
Human studies
- Outcome trialsDecades of trials show ACE inhibitors reduce heart attacks, strokes, heart failure and death in people with high blood pressure or heart disease. The HOPE trial of ramipril, a related drug, showed these benefits in high-risk patients.
- AgingNo trial has tested ACE inhibitors for aging in healthy people with normal blood pressure.
Safety and side effects
A dry cough affects around one in ten people. ACE inhibitors can raise potassium, affect kidney function and cause dizziness. Rarely they cause angioedema, a serious swelling of the face and throat. They must not be used in pregnancy. Captopril is short-acting and needs two or three doses a day.
Our view
A modest mouse signal and a strong rationale, but the size of the effect is small and there are no human aging data. Its real value is in treating high blood pressure.
Sources
- Strong et al., Aging Cell 2022: captopril and lifespan in mice
- Benigni et al., J Clin Invest 2009: AT1 receptor disruption promotes longevity
- HOPE trial, NEJM 2000: ramipril in high-risk patients
- ClinicalTrials.gov: registered studies of Captopril
Links open PubMed or ClinicalTrials.gov searches for each study.
Last reviewed 11 November 2026. General information, not medical advice. None of these drugs is approved to slow aging.